- Home
- OTLK vs DYOR Comparison
OTLK vs DYOR Comparison
Compare OTLK & DYOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OTLK | DYOR |
|---|---|---|
| Founded | 2010 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.6M | 231.8M |
| IPO Year | 2016 | 2025 |
Fundamental Metrics
Financial Performance| Metric | OTLK | DYOR |
|---|---|---|
| Price | $0.52 | $10.16 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.03 | N/A |
| AVG Volume (30 Days) | ★ 3.8M | 17.9K |
| Earning Date | 08-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.91 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,146,123.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6,355.64 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $9.87 |
| 52 Week High | $2.54 | $10.47 |
Technical Indicators
Market Signals| Indicator | OTLK | DYOR |
|---|---|---|
| Relative Strength Index (RSI) | 40.37 | 67.48 |
| Support Level | $0.40 | $9.93 |
| Resistance Level | $0.72 | $10.19 |
| Average True Range (ATR) | 0.05 | 0.00 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 50.19 | 100.00 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About DYOR Insight Digital Partners II Class A Ordinary Shares
Insight Digital Partners II is a blank check company.